Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. (PubMed, J Clin Med) - Sep 16, 2026 - "The purpose of this umbrella review is to summarize current knowledge concerning the efficacy and safety of FDA- and EMA-approved AAAs for AD, namely, lecanemab and donanemab. They are, however, associated with increased ARIA risk. Their administration depends upon careful patient selection, shared decision-making, and clear communication regarding expectations."
Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia • Hematological Disorders
|
|
Antonis Frontistis; Dimitrios Michmizos; Effrosyni Koutsouraki; Francesca Zuchi; Iraklis Keramidiotis; Stefania Kalampokini; Vasileios Papaliagkas
|